GUILFORD, Conn., Sept. 17, 2019 — InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, today announced the expansion of its flagship AI- and ML-driven innovation monitoring platform, AlphaMeld®. This expansion will provide a suite of products to facilitate the democratization of data analysis across the life sciences value chain.
CIMeld™, an AlphaMeld® powered product, will be launched at the upcoming PharmaCI USA 2019 Conference and Exhibition, where competitive intelligence executives in pharma, biotech and medical devices meet at one of the largest CI assemblies in the world. CIMeld™ is a unique product that takes advantage of the digital data deluge and leverages AI-powered technology to triangulate signals from multiple sources to generate insights and identify opportunities and threats across diseases, companies, drug portfolios, and early innovation.
The AlphaMeld® suite of products is accessible via a secure, customized, cloud-based interface with the option to personalize the definition of success and failure that lends a unique competitive advantage to its users. Together with InveniAI's broad domain expertise, stakeholders can leverage an integrated platform built on 15 years of data sets that have been cleaned, curated, connected and customized with AI/ML algorithms to address specific business questions.
"With the rapid uptake of AlphaMeld®'s technology, and based on customer feedback, we have created a product line that has broad stakeholder appeal within the life sciences," said Krishnan Nandabalan, Ph.D., President and CEO of InveniAI. "Our platform is commercially validated with multiple clinical candidates – the most advanced program will be entering pivotal trials and numerous other programs entering human proof of concept trials."